Skip to content
Peptide research

Kisspeptin-10

Also known as Metastin Fragment · KP-10
Category
Hormone & Sexual Health
Administration routes
Injectable
Regulatory status
Not FDA-approved

Kisspeptin-10 is a synthetic hormone fragment used experimentally to trigger GnRH and LH/FSH release for fertility research, including IVF triggering and testosterone support. GnRH stimulation and IVF triggering have moderate human support, but amenorrhea reversal and anti-cancer claims are speculative. Repeated dosing can desensitize the reproductive axis, and no long-term human safety data exist. It is not FDA-approved, and WADA explicitly listed kisspeptin and its agonist analogues as prohibited at all times in males from 2024.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Kisspeptin-10 is the smallest active fragment of the kisspeptin family, a group of brain hormones that serve as the master switch for the reproductive system. This 10-amino-acid peptide is the most potent known natural activator of the hormone cascade that controls fertility, puberty, and sex hormone production. It works at the very top of the chain: kisspeptin signals GnRH neurons in the brain, which then trigger LH and FSH release from the pituitary, which in turn drive testosterone, estrogen, and progesterone production. Originally identified as a tumor suppressor (called metastin), its critical role in reproduction was discovered when genetic mutations in this pathway were found to cause either absent puberty or precocious puberty.

How it works in the body

Binds to the KISS1R (GPR54) receptor on GnRH neurons in the hypothalamus. This triggers a burst of GnRH release, which causes the pituitary to release LH and FSH. Kisspeptin is the master upstream regulator of the reproductive hormone axis — it essentially 'turns on' puberty and maintains fertility.

Research overview

Kisspeptin is one of the most intensely studied hormones in reproductive endocrinology, with over 3,000 papers published since the discovery of its reproductive role in 2003. Human clinical studies (Phase 1-2) show that kisspeptin robustly stimulates LH release in men (2-3 fold increases), with an interesting sex difference: women in the early follicular phase barely respond, while women near ovulation respond strongly. KP-54 triggered egg maturation in IVF studies; a retrospective comparison found lower OHSS odds than hCG. A 2023 randomized crossover trial found penile tumescence up to 56% greater than placebo during a sexual video in men with low desire. A 2025 study demonstrated successful nasal spray delivery in humans. All therapeutic uses remain in early-to-mid-stage clinical trials.

Who researches Kisspeptin-10?

Commonly researched by

  • People exploring hormone and sexual health

    Researched for effects on hormone levels, sexual function, or fertility.

  • People researching gnrh and gonadotropin stimulation

    One of the primary studied benefits of Kisspeptin-10.

Important considerations for

  • Those with Hormone-sensitive cancers

    High

    Stimulates GnRH -> LH/FSH -> sex hormone production. May promote hormone-dependent tumor growth.

  • Those who are pregnant or breastfeeding

    Absolute

    Disrupts reproductive hormone signaling.

Safety & interactions

Do not use if

  • Hormone-sensitive cancers

    High

    Stimulates GnRH -> LH/FSH -> sex hormone production. May promote hormone-dependent tumor growth.

General cautions

  • Pregnancy (except controlled IVF use)

    Absolute

    Disrupts reproductive hormone signaling.

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(9)

Rated by level of concern

  • Very short half-life (~4 minutes for KP-10) limits practical clinical utility without continuous infusion

    High

    PMID 26089302 (Hum Reprod 2015, direct IV comparison of KP-10, KP-54 and GnRH in healthy men); PMID 21632807 (KP-10 infusions up to 22.5 h). Half-life figure: human kisspeptin PK literature.

  • Tachyphylaxis with continuous/daily dosing — chronic exposure desensitizes GnRH neurons and paradoxically suppresses gonadotropins

    High

    PMID 16469799 (Endocrinology 2006, continuous metastin 45-54 desensitizes GPR54-induced GnRH release, juvenile male rhesus); PMID 17412800 (Endocrinology 2007, adult male rhesus); PMID 20980998 (twice-daily KP-54 = complete tolerance; twice-weekly = partial)

  • No long-term human safety data — all clinical studies involve short-duration exposure

    High

    PMID 20980998 (8-week twice-weekly dosing, the longest published human exposure); PMID 36147569 (review, notes short-exposure trial designs)

  • Sexual dimorphism in response — minimal effect in follicular-phase women, unpredictable in some populations

    Moderate

    PMID 21976724 (JCEM 2011, effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans; IV bolus, SC bolus and IV infusion)

  • Not FDA-approved — no standardized pharmaceutical-grade formulations available outside research settings

    High

    FDA Drugs@FDA — no approved kisspeptin product; https://www.accessdata.fda.gov/scripts/cder/daf/

  • Unregulated products sold online may have variable purity and quality

    High

    FDA guidance on compounded/unapproved peptide drug products; https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding

  • Potential appetite suppression reported anecdotally; interaction with metabolic pathways not fully characterized

    Theoretical

    Mechanistic/rodent literature on kisspeptin and energy balance; no controlled human appetite endpoint published; PMID 20980998 (no adverse effects reported over 8 weeks)

  • Theoretical concern: chronic HPG axis suppression via desensitization could impair fertility if dosed incorrectly

    Theoretical

    PMID 16469799; PMID 17412800 (primate desensitization); PMID 20980998 (human tachyphylaxis is schedule-dependent); human fertility outcome not studied

  • WADA prohibited in males since 2024 — implications for competitive athletes

    Low

    WADA Prohibited List, section S2.2 (gonadotrophin releasing factors, prohibited in males); https://www.wada-ama.org/en/prohibited-list

Interaction summary(8)

Rated by direction with this peptide

  • GnRH antagonists (cetrorelix, ganirelix, degarelix) and GnRH agonists (leuprolide, triptorelin)

    CautionModerate

    Kisspeptin acts entirely upstream by releasing endogenous GnRH, so pituitary GnRH-receptor blockade or agonist-induced downregulation abolishes its gonadotropin effect — expect no LH/FSH response at all. This is loss of effect rather than toxicity, but it is a hard mechanistic block.

    Mechanistic; the human KP-10 vs KP-54 vs GnRH comparison (PMID 26089302) establishes that kisspeptin's gonadotropin effect is GnRH-mediated. No trial has co-administered kisspeptin with a GnRH antagonist as a formal interaction study.

  • hCG and other IVF trigger agents (in controlled ovarian stimulation)

    CautionModerate

    Kisspeptin's OHSS-sparing advantage as a trigger depends on producing a short, physiological LH surge; adding or substituting hCG reintroduces the sustained luteotropic stimulus that drives OHSS and negates the benefit. Note this evidence is for KP-54, not KP-10.

    PMID 26192876 (KP-54 trigger in women at high OHSS risk); PMID 36147569 (review comparing LH-response duration of kisspeptin, hCG and GnRHa triggers)

  • Exogenous testosterone / anabolic-androgenic steroids

    CautionLow

    Androgen negative feedback suppresses hypothalamic Kiss1/KNDy neurons and the GnRH pulse generator, so the LH/testosterone response to kisspeptin is expected to be blunted during exogenous androgen use. This is anticipated loss of efficacy, not a toxic interaction, and it is mechanistic only; no human data support using kisspeptin during or after androgen use as an 'axis restart'.

    Mechanistic (sex-steroid feedback on KNDy/Kiss1 neurons); no human study of kisspeptin during androgen exposure

  • Estrogen/progestin contraceptives and sex-steroid therapy

    CautionLow

    The gonadotropin response to kisspeptin is strongly sex-steroid- and menstrual-phase-dependent — absent in follicular-phase women, present preovulatory — so hormonal contraception makes the response unpredictable to absent. The concern is unpredictable efficacy, not a documented harm.

    PMID 21976724 (menstrual-phase dependence and sexual dimorphism of the human KP-10 response)

  • Prolactin-raising drugs (risperidone, haloperidol, amisulpride, metoclopramide, domperidone)

    CautionTheoretical

    Drug-induced hyperprolactinemia suppresses hypothalamic kisspeptin signalling, so these agents plausibly blunt the endogenous axis kisspeptin is meant to drive. Shown in mice with infused prolactin; never tested as a drug interaction in humans.

    PMID 23006326 (prolactin suppresses hypothalamic Kiss1 neurons in mice)

  • Dopamine agonists (cabergoline, bromocriptine)

    NeutralTheoretical

    There is no human co-administration data and no evidence of additive benefit. In hyperprolactinemic states, lowering prolactin restores endogenous kisspeptin tone through the same pathway exogenous kisspeptin targets, so the two are largely redundant rather than harmful — and cabergoline is the evidence-backed option.

    PMID 23006326 (mechanistic overlap, mouse model; no human co-administration study)

  • Opioids (chronic use, including methadone/buprenorphine)

    CautionTheoretical

    Opioid signalling — including dynorphin within the KNDy neuron system — inhibits GnRH pulse generation, so opioid-induced hypogonadism may attenuate or distort the kisspeptin response.

    KNDy-neuron (kisspeptin/neurokinin B/dynorphin) physiology; no controlled human interaction study

  • Clomiphene, letrozole and other SERM/aromatase-inhibitor axis stimulants

    CautionTheoretical

    These raise LH/FSH by removing estrogen negative feedback while kisspeptin drives GnRH release directly, so combined use would be additively gonadotropin-stimulating. Severity set to Theoretical: the combination is entirely unstudied and the 'overshoot' concern is inferred from mechanism, not observed.

    Mechanistic; no published co-administration data

Known risks(9)

  • Very short half-life (~4 minutes for KP-10) limits practical clinical utility without continuous infusion

  • Tachyphylaxis with continuous/daily dosing — chronic exposure desensitizes GnRH neurons and paradoxically suppresses gonadotropins

  • No long-term human safety data — all clinical studies involve short-duration exposure

  • Sexual dimorphism in response — minimal effect in follicular-phase women, unpredictable in some populations

  • Not FDA-approved — no standardized pharmaceutical-grade formulations available outside research settings

  • Unregulated products sold online may have variable purity and quality

  • Potential appetite suppression reported anecdotally; interaction with metabolic pathways not fully characterized

  • Theoretical concern: chronic HPG axis suppression via desensitization could impair fertility if dosed incorrectly

  • WADA prohibited in males since 2024 — implications for competitive athletes

Drug interactions(6)

  • GnRH agonists (leuprolide, goserelin)

    Both stimulate GnRH signaling. Combined use may cause excessive gonadotropin stimulation acutely or accelerate desensitization/downregulation of the HPG axis.

  • GnRH antagonists (cetrorelix, ganirelix)

    GnRH antagonists block GnRH receptors on the pituitary, potentially blunting the downstream effects of kisspeptin-stimulated GnRH release.

  • Dopamine agonists (cabergoline, bromocriptine)

    Dopamine agonists lower prolactin, which may affect kisspeptin neuron activity. Kisspeptin has shown potential to overcome dopamine-agonist-resistant hyperprolactinemia.

  • Exogenous sex steroids (testosterone, estradiol, progesterone)

    Sex steroids exert feedback on kisspeptin neurons. Exogenous testosterone/estrogen may alter kisspeptin responsiveness through negative feedback on KISS1 expression.

  • Opioids (morphine, fentanyl)

    Dynorphin (an endogenous opioid) is a co-transmitter in KNDy neurons that inhibits kisspeptin signaling. Exogenous opioids may suppress kisspeptin-driven GnRH pulsatility.

  • Neurokinin B receptor agonists

    NKB is a co-transmitter in KNDy neurons that stimulates kisspeptin release. NKB agonists may potentiate kisspeptin's effects on GnRH pulsatility.

Research & benefits

Evidence base

Evidence Level
Phase 1-2
Total Studies
50
Human Studies
18

Approximately 50 published studies with human data, including ~18 clinical trials or interventional studies. Most involve healthy volunteers or small patient cohorts (10-50 subjects). The largest IVF trial included 60 women. A 2023 JAMA Network Open RCT (n=32) demonstrated efficacy for HSDD. No Phase 3 trials completed. Evidence is strongest for IVF oocyte maturation triggering and GnRH/LH stimulation.

Researched for(8)

Rated by confidence in the evidence

  • GnRH and gonadotropin stimulation

    High

    Multiple human trials confirm IV KP-10 raises LH and pulse frequency.

    PMID 21632807 (JCEM 2011, KP-10 stimulates LH and increases pulse frequency in men; IV bolus 0.01-3.0 ug/kg and infusions up to 22.5 h); PMID 26089302 (Hum Reprod 2015, single-blind placebo-controlled direct comparison of IV KP-10, KP-54 and GnRH in healthy men, n=5 per dose group)

  • Safer IVF oocyte maturation trigger

    Medium

    Human dose-finding trial used kisspeptin-54, not KP-10, with no head-to-head trigger comparison.

    PMID 26192876 (JCEM 2015, phase 2 open-label randomised dose-finding, KP-54 trigger in 60 women at high OHSS risk); PMID 36147569 (Front Endocrinol 2022, review of kisspeptin as IVF trigger)

  • Restoration of reproductive function in hypothalamic amenorrhea

    Low

    Small studies with KP-54 increased LH pulsatility, but no restored ovulation or fertility shown.

    PMID 24517142 (JCEM 2014, IV KP-54 increased LH pulsatility in 5 women with hypothalamic amenorrhoea); PMID 20980998 (Clin Pharmacol Ther 2010, twice-weekly KP-54 for 8 weeks; twice-daily caused tachyphylaxis)

  • Sexual desire and arousal enhancement

    Medium

    RCTs used kisspeptin-54, not KP-10, on brain imaging and arousal measures, single infusion.

    PMID 36735255 (JAMA Netw Open 2023, KP-54 infusion, men with HSDD); PMID 36287566 (JAMA Netw Open 2022, KP-54 infusion, 32 women with HSDD)

  • Testosterone stimulation in men

    Medium

    Small acute IV KP-10 trials raised testosterone and LH in men, no sustained-dosing data.

    PMID 23153270 (Clin Endocrinol 2013, KP-10 stimulates testosterone and LH in 5 men with T2D and mild hypogonadism); PMID 21632807

  • Potential diagnostic tool

    Speculative

    Proposed challenge test for GnRH function, no validated protocol or diagnostic study yet.

    Mechanism-plus-pilot only; the direct KP-10/KP-54/GnRH comparison in humans (PMID 26089302) establishes the pharmacological basis for such a test but is not a diagnostic-accuracy study.

  • Reversal of hyperprolactinemia-induced amenorrhea

    Speculative

    An exploratory human KP-10 study in two women increased reproductive hormones, but did not establish restored menstrual cycles or fertility.

    PMID 23006326 (J Clin Invest 2012, Sonigo et al., hyperprolactinemia-induced ovarian acyclicity reversed by kisspeptin in mice)

  • Anti-metastatic properties

    Speculative

    KISS1 gene suppresses metastasis in lab models, no human trial of injected KP-10 exists.

    PMID 8944003 (JNCI 1996, Lee et al., KiSS-1 as a human malignant melanoma metastasis-suppressor gene)

Benefits(8)

  • GnRH and gonadotropin stimulation

  • Safer IVF oocyte maturation trigger

  • Restoration of reproductive function in hypothalamic amenorrhea

  • Sexual desire and arousal enhancement

  • Testosterone stimulation in men

  • Potential diagnostic tool

  • Reversal of hyperprolactinemia-induced amenorrhea

  • Anti-metastatic properties

Key studies(6)

  1. Jayasena CN et al.

    J Clin Endocrinol Metab

    2011

    KP-10 robustly stimulated LH in men at all doses (0.3-10 nmol/kg IV) but failed to stimulate gonadotropins in follicular-phase women; 200-fold greater plasma kisspeptin was needed. Half-life ~4 minutes.

  2. Skorupskaite K, George JT, Anderson RA

    Hum Reprod Update

    2014

    Comprehensive review establishing kisspeptin as upstream regulator of GnRH. KP-54 sustained reproductive-hormone responses over eight weeks, but partial desensitization still occurred. Kisspeptin-54 achieved live birth as IVF trigger.

  3. Mills EG, Ertl N, Wall MB et al.

    JAMA Network Open

    2023

    Kisspeptin (1 nmol/kg/h IV) significantly enhanced sexual brain processing (Cohen d=0.81, P=.003), increased penile tumescence by 56% vs placebo (P=.02), and increased happiness about sex. No adverse events.

  4. Kotanidou S, Nikolettos N, Kritsotaki N et al.

    J Clin Med

    2025

    Comprehensive review of kisspeptin in fertility, covering a retrospective KP-54 comparison that found lower OHSS odds than hCG, the MVT-602 agonist's superior PK with a triphasic LH pattern, and KP-10 reversal of hyperprolactinemia-induced amenorrhea.

  5. Intranasal kisspeptin administration rapidly stimulates gonadotropin release in humans

    Randomized, double-blinded, crossover, placebo-controlled trialAcute dosing

    Multiple authors

    eBioMedicine (The Lancet)

    2025

    Intranasal kisspeptin-54 rapidly stimulated gonadotropin release in healthy men, women, and patients with hypothalamic amenorrhoea. No side effects or adverse events. Formulation stable for 60 days at 4C.

  6. Xie Q, Kang Y, Zhang C et al.

    Front Endocrinol

    2022

    Kisspeptin activates PLC-beta via KISS1R leading to calcium mobilization and ERK1/2/p38 MAPK phosphorylation. KNDy neurons (kisspeptin/neurokinin B/dynorphin) control GnRH pulse generation. Therapeutic potential for PCOS, infertility, and androgen-dependent malignancies.

What research suggests over time

  • Hours-Days

    Phase 1

    Single IV dose (0.3-10 nmol/kg) robustly stimulates LH release in healthy men within 1 hour.

  • Weeks 2-4

    Phase 1-2

    Twice-weekly SC dosing sustains gonadotropin release in early-phase trials; sexual brain processing improvements in HSDD (Cohen d=0.81, JAMA Netw Open 2023).

  • Long-term

    Phase 1-2

    ~50 published human studies; ~18 interventional trials. IVF and HSDD trials ongoing. FDA Category 2 — not approved.

Regulation & availability

Why researchers look at it

Sits at the very top of the hormonal cascade controlling fertility — above GnRH, LH, FSH, and the sex hormones — with a retrospective KP-54 comparison finding lower OHSS odds than hCG in IVF. A 2023 JAMA Network Open crossover RCT (n=32) found penile tumescence up to 56% greater than placebo during a sexual video, and a 2025 study demonstrated successful nasal spray delivery. If larger Phase 3 trials confirm these results, kisspeptin could become a safer standard in fertility medicine and open new directions in sexual health.

Estimated cost
No approved product and no verified reference price
FDA status
Not FDA-approved. Kisspeptin-10 remains FDA 503A Category 2 (bulk substances that may present significant safety risks) and is ineligible for routine patient-specific compounding; an FDA advisory committee voted against adding it to the compounding list in October 2024. Human use remains investigational; MVT-602 is a separate investigational receptor agonist.
WADA status
Prohibited in males. Kisspeptin was added to the WADA Prohibited List effective January 1, 2024, classified under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) as a testosterone-stimulating peptide. Kisspeptin and its agonist analogues (including MVT-602/TAK-448) are banned in-competition and out-of-competition for male athletes. Status for female athletes may differ as it is specifically listed under testosterone-stimulating peptides prohibited in males.
Prescribability
Kisspeptin-10 is not FDA-approved and is not eligible for compounding: FDA lists it as a bulk substance that may present significant safety risks (Category 2), and an FDA advisory committee voted against adding it to the compounding list in October 2024. Investigational only.
Availability
Kisspeptin-10 remains FDA 503A Category 2 and is not eligible for routine compounding. Clinic advertising does not establish lawful compounding eligibility. Clinical-grade kisspeptin, often KP-54, is used in supervised research, including investigational settings at research hospitals such as Imperial College London. The kisspeptin receptor agonist MVT-602 (TAK-448) is in clinical development by Takeda/Myovant Sciences.

International status

  • EU

    Not approved

  • UK

    Used in research settings (Imperial College London studies)

  • US

    Kisspeptin-10 is not FDA-approved and is not eligible for compounding: FDA lists it as a bulk substance that may present significant safety risks (Category 2), and an FDA advisory committee voted against adding it to the compounding list in October 2024.

Regulatory timeline(11)

  1. 2003
    Discovery that KISS1R (GPR54) mutations cause hypogonadotropic hypogonadism, establishing kisspeptin's essential role in reproduction
  2. 2005
    First human administration of kisspeptin-54 demonstrating potent LH stimulation in healthy men
  3. 2011
    Jayasena et al. publish definitive study on kisspeptin-10 sexual dimorphism in JCEM (n=46)
  4. 2014
    First live birth achieved using kisspeptin-54 as IVF oocyte maturation trigger, replacing hCG
  5. 2014
    Comprehensive review in Human Reproduction Update establishes clinical kisspeptin-GnRH pathway framework
  6. 2019
    MVT-602 (kisspeptin receptor agonist) enters Phase 2 clinical trials for assisted reproduction
  7. 2023
    JAMA Network Open RCT (n=32) demonstrates kisspeptin efficacy for hypoactive sexual desire disorder in men
  8. 2024
    WADA adds kisspeptin to Prohibited List as testosterone-stimulating peptide (effective Jan 1, 2024)
  9. 2024
    MVT-602 Phase 2 trials show triphasic LH pattern mimicking physiologic midcycle surge
  10. 2025
    Intranasal kisspeptin-54 delivery demonstrated in randomized controlled trial (eBioMedicine)
  11. 2025
    Comprehensive J Clin Med review consolidates kisspeptin fertility applications including IVF, OHSS prevention, cryopreservation

Sources & FAQs

Research sources(8)

Frequently asked questions(6)

What is the difference between Kisspeptin-10 and Kisspeptin-54?

Both are fragments of the full-length kisspeptin-145 protein. Kisspeptin-10 is the minimal 10-amino-acid C-terminal fragment that retains full KISS1R binding activity. Kisspeptin-54 is the longer 54-amino-acid form with a longer half-life (~28 min vs ~4 min for KP-10) and is used in most clinical trials. Both activate the same receptor and stimulate GnRH release.

Why does kisspeptin-10 affect men and women differently?

Studies show striking sexual dimorphism. Men show robust LH increases at all doses tested, while women in the follicular phase show minimal response — even at 200-fold greater plasma concentrations. Women only respond strongly in the preovulatory phase when estrogen levels are high, suggesting estrogen priming of the kisspeptin-GnRH axis is required for female responsiveness.

Can kisspeptin-10 replace testosterone replacement therapy?

Kisspeptin stimulates endogenous testosterone production through the natural HPG axis rather than providing exogenous testosterone. This theoretically preserves fertility and testicular function. However, kisspeptin-10's very short half-life (~4 min) and the risk of tachyphylaxis with continuous dosing make it impractical for chronic TRT replacement with current formulations. Longer-acting analogs like MVT-602 may address this.

Is kisspeptin safe?

In clinical trials involving hundreds of subjects, kisspeptin has been well tolerated with no serious adverse events reported. Common mild effects include injection site reactions, transient flushing, and headache. A 2023 RCT in 32 men reported zero adverse events. However, long-term safety in diverse populations has not been established, and all use remains investigational.

What is tachyphylaxis and why does it matter for kisspeptin?

Tachyphylaxis is a decrease in response to repeated dosing. Continuous daily kisspeptin administration can cause GnRH neuron desensitization, actually reducing gonadotropin and sex steroid levels — the opposite of the desired effect. This has been exploited therapeutically (e.g., for prostate cancer suppression) but is a limitation for fertility/hormonal use. Studies of intermittent dosing have avoided this problem.

How is kisspeptin used in IVF?

Kisspeptin-54 has been used as an alternative to hCG for triggering final oocyte maturation in IVF. A retrospective KP-54 comparison found lower OHSS odds than hCG; randomized comparative safety evidence remains limited.